The lack of capital - other than being acquired, what other alternatives are there? Even then RGRX may get a reasonable price but it isn't like it can negotiate from a position of strength.
in two weeks. Which means some time next week we should get some significant news. but we have already learned about the registration of the product in Russia and most people think that was good news, but I don't believe that is the news Dr. Chan was referring too.
Sno - best to your son and your family, it sounds as if his cancer is treatable. His youth will greatly assist in his recovery.
When you posted about your son's brain cancer, it brought back memories of Westcoastdoc.
Again, good luck to you.
Bertha - I was wondering why no mention of the cardiac partner was made during the cc. So I sent an email to Amy V. asking about it. Sometimes she answers and some times she doesn't.
Saw - we have begun the FDA process with the REFRESH trial. That should complete enrollment in a few months.
PR just out !
It is a micro cap with a product that works - many took a position in CTSO years ago. I did likewise but the only real cost is an opportunity cost is being here when I could have been elsewhere. But a new investor buying today will see a very nice return considering the time value of money.
Pearsby09, for the short period that you were absent from this message board, the pps recovered nicely, so....if you really love your MB family and really cared about their financial well being you would make the ultimate sacrifice for your fellow humans and vacate this board.
It is impressive that a provider sees their own empirical evidence that the filter is beneficial to the patient that they willingly adopt the filter.
The CTSO website has a summary of the 3rd user conference. I particularly liked the summary ".... In a cardiac surgery evaluation performed at Angers, France, CytoSorb® was used intra-operatively on 10 patients undergoing a diverse set of complex cardiac surgery procedures, similar to patients in the U.S. REFRESH I trial. All ten patients did well, with CytoSorb® credited with helping to stabilize two hemodynamically unstable patients going into extensive and complicated surgery, and reducing the need for vasopressors and extensive, costly, and risky extracorporeal life support that would normally be required in the post-operative period in these patients."
The REFRESH trial should give everyone a lot to look forwards too.